News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sirna Therapeutics (RNAI) Reports 2004 Fourth Quarter And Full Year Financial Results


10/19/2005 5:12:46 PM

BOULDER, Colo., Feb. 18 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. today reported a net loss applicable to common stock of $8.9 million, or $0.23 per share, for the quarter ended December 31, 2004 compared to $6.1 million, or $0.19 per share, for the same period in 2003. Net loss applicable to common stock for the year ended December 31, 2004 was $28.9 million, or $0.81 per share, compared to $30.4 million, or $1.31 per share, for the same period last year.

Research and development expenses were $5.9 million and $21.8 million for the three and twelve-month periods ended December 31, 2004, respectively, compared to $5.1 million and $23.5 million for the same periods in 2003.

In December 2004, the Company announced the first program to apply RNA interference (RNAi) technology to dermatology, with an initial focus on hair removal. Sirna, in the formation of its dermatology division, acquired Skinetics Biosciences, Inc., for $1.9 million, of which $1.5 million was in Sirna Common Stock and the granting of future milestone payments and royalties. The acquisition cost of Skinetics Biosciences is reflected as a separate line item, "write-off of acquired in-process research and development" in the Company's statement of operations for the period ended December 31, 2004.

In December 2004, the Company announced that it raised $6.8 million from some of its largest stockholders, Sprout Group, Venrock Associates, Oxford Bioscience Partners and Granite Global Ventures, through the restructuring and exercise of 2.7 million warrants. In the completed warrant restructuring and exercise, the parties in the aggregate exercised 2.7 million warrants and received 2.7 million common stock shares representing an approximate 7% increase in issued and outstanding shares of the Company.

The Company's cash, cash equivalents and securities available-for-sale were $36.1 million as of December 31, 2004.

"Sirna is making excellent progress in transitioning its platform RNA interference (RNAi) technology from the lab into clinical development. In November, Sirna initiated, ahead of schedule, its Phase 1 clinical trial for its most advanced compound, Sirna-027, a chemically modified siRNA to treat age-related macular degeneration (AMD). Additionally, Sirna's product development pipeline is replete with therapeutic targets that offer significant market opportunity," stated Howard W. Robin, Chief Executive Officer of the Company. "We believe short interfering RNAs (siRNAs) will become a ubiquitous class of therapeutics and that Sirna will continue in its leadership role in the discovery of novel RNAi technologies and development of important and therapeutically relevant siRNA products."

  2004 Highlights

   * Initiated first clinical trial of a chemical modified siRNA, Sirna-027,
     for the treatment of age-related macular degeneration (AMD).

   * Discovered multifunctional siRNAs capable of inhibiting multiple gene
     targets simultaneously.

   * Demonstrated unprecedented systemic delivery of an siRNA to the liver,
     specifically directed toward the treatment of chronic hepatitis and
     diabetes.

   * Completed in vivo proof-of-concept research on direct delivery of an
     siRNA to the brain for the treatment of Huntington's disease through
     the efforts of Dr. Beverly Davidson, University of Iowa. Sirna entered
     into an exclusive license agreement with the University of Iowa with
     respect to Dr. Davidson's research.

   * Completed in vivo proof-of-concept research on delivery of an siRNA to
     the lung for the treatment of asthma through the efforts of Dr. Erwin
     Gelfand, National Jewish Medical and Research Center.

   * Formed Dermatology Division to focus on the topical delivery of siRNAs,
     the first indication of which will be directed towards permanent hair
     removal. Sirna Dermatology is based upon the research of Dr. Angela
     Christiano, which was acquired through Skinetics Biosciences, Inc., and
     an exclusive license from Columbia University. Sirna has also assembled
     a world renowned Scientific Advisory Board in the field of dermatology.

   * Expanded patent portfolio on RNAi technology through continued
     breakthrough innovations at Sirna and in-licensing activities.

   * Raised $25.5 million in cash ($18.7 million from a private investment
     from new shareholders in May and $6.8 million through the exercise of
     warrants from existing shareholders in December).

   About Sirna Therapeutics

Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age- related macular degeneration (AMD), Huntington's disease, diabetes, asthma, oncology, and hair removal. Sirna has initiated a Phase 1 clinical trial for its most advanced compound, Sirna-027, a chemically modified siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. The Company has strategic partnerships with Eli Lilly, Targeted Genetics and Archemix and a leading intellectual property portfolio in RNAi. More information on Sirna Therapeutics is available on the Company's web site at http://www.sirna.com/ .

Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, there is a very significant risk that promising pre-clinical results cannot be reproduced in the clinic. Furthermore, Sirna's ability to develop products and to operate as a going concern are contingent upon having readily available cash to fund its operating programs and are subject to the escalating expenses and risks associated with the initiation of clinical trials and their potential outcomes. Other risks and uncertainties include Sirna's early stage of development and short operating history, whether Sirna can achieve and maintain profitability, whether Sirna can obtain and protect patents, the risk of third-party patent infringement claims, whether Sirna can engage collaborators and obtain regulatory approval for products, Sirna's concentration of stock ownership, and availability of materials for product manufacturing. These and additional risk factors are identified in Sirna's Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT: Martin E. Schmieg, Sr. Vice President & CFO of Sirna Therapeutics, Inc., +1.303.449.6500 Gregory Tiberend, The Ruth Group, +1.646.536.7005 SIRNA THERAPEUTICS, INC. CONDENSED BALANCE SHEET (in thousands) December 31, December 31, 2004 2003 Assets Cash, cash equivalents and securities available-for-sale $36,083 $ 36,624 Accounts receivable 66 156 Equipment & leasehold improvements, net 2,507 3,402 Other assets, net 2,901 2,502 Total assets $41,557 $42,684 Liabilities and stockholders' equity Current liabilities $ 6,855 $ 4,042 Long-term liabilities, long-term debt & convertible debt 375 3,868 Stockholders' equity 34,327 34,774 Total liabilities & stockholders' equity $ 41,557 $ 42,684 SIRNA THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three months ended Twelve months ended December 31, December 31, 2004 2003 2004 2003 Total revenues $691 $420 $1,547 $4,175 Expenses Cost of goods sold 129 -- 129 -- Research and development 5,913 5,059 21,800 23,460 General and administrative 1,686 1,517 6,740 5,005 Write-off of acquired in-process R&D 1,883 -- 1,883 -- Write-off of patent costs -- -- -- 5,344 Total expenses 9,611 6,576 30,552 33,809 Operating loss (8,920) (6,156) (29,005) (29,634) Other income (expense) Interest income, net 61 9 148 2 Equity in loss of unconsolidated affiliate -- 1 -- (209) Total other income (expense) 61 10 148 (207) Net loss (8,859) (6,146) (28,857) (29,841) Accretion of dividends on preferred stock -- -- -- 562 Net loss applicable to common stock $(8,859) $(6,146) $(28,857) $(30,403) Net loss per share (basic and diluted) $(0.23) $(0.19) $(0.81) $(1.31) Shares used in computing net loss per share 38,209,069 31,638,625 35,795,069 23,278,591

Sirna Therapeutics, Inc.

CONTACT: Martin E. Schmieg, Sr. Vice President & CFO of SirnaTherapeutics, Inc., +1-303-449-6500; or Gregory Tiberend of The Ruth Group,+1-646-536-7005, for Sirna Therapeutics, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES